Biotech Values

[mcbio]

Re: CLDX 2Q12 CC notes

One other important point I took away from the CC:

(~7 minute mark) Regarding durability of response and PFS with CDX-011, the Kaplan-Meier curves show improvement in PFS in triple-negative patients overall with 011 but more significant in high-GPNMB expressors and most marked in combined group where difference between curves meets statistical significance despite small numbers. I took this as an update on what they are seeing with the results right now, or at least very recent, as opposed to CLDX just referencing the data that was reported in May. Obviously we need to wait for the more formal update in 4Q12 at SABS but I think the comments here were encouraging.